Plain-English translation of NCT07436741 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether surufatinib, a new medication, works better when combined with two standard chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that may be removable by surgery. Some participants will receive the new medication plus both chemotherapy drugs, while others will receive just the two chemotherapy drugs alone. The goal is to see if adding this medication helps shrink tumors and improve outcomes before surgery.
Pancreatic cancer is a serious disease, and even when surgery is possible, the cancer often comes back. This trial is testing whether this medication can make the chemotherapy work better and give patients a better chance of staying cancer-free after surgery.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the new medication combined with two chemotherapy drugs, or just the two chemotherapy drugs alone, given before your pancreatic cancer surgery. You will attend multiple clinic visits for blood tests, imaging scans, and to monitor how you are responding to treatment. After completing the chemotherapy phase, you will have surgery to remove the cancer, followed by standard follow-up care.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
China